Skip to main content
Explore URMC
menu

Stage II-IV Ovarian or Primary Peritoneal Cancer: Treatment with Letrozole with or without Paclitaxel and Carboplatin

Research Question:
How well does letrozole - with or without paclitaxel and carboplatin - work in treating patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum?

Basic Study Information

Purpose:
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary or peritoneum compared to paclitaxel and carboplatin without letrozole.

Location: University of Rochester Medical Center
Study Reference #: CGYM19142

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search